Diagnostic Center | September 01, 2022
Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
Merck’s first microbiology application and training lab in India
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Subscribe To Our Newsletter & Stay Updated
